Teva Anagrelide Capsules Recall: Failed Dissolution Testing Risk
Teva recalls 0.5mg Anagrelide Capsules due to failed dissolution testing. This may affect medication effectiveness. Check NDC 0172-5241-60 and lot # GD01090.
Lower-risk recall
Failed Dissolution Specifications- Low Out-Of-Specification results obtained during stability testing.
Contact the company
What happened, in plain English
Teva is recalling 0.5 mg Anagrel: 100-count capsules that failed dissolution testing. This could mean the medication doesn't work as intended, so affected users should contact their doctor. Read more at govinfonow.com/recall/34726-teva-anagrelide-capsules-recall-failed-dissolution-testing-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/34726-teva-anagrelide-capsules-recall-failed-dissolution-testing-risk · Updated August 18, 2026 · FDA enforcement record: FDA #D-0992-2022
Cite this page
“Teva Anagrelide Capsules Recall: Failed Dissolution Testing Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/34726-teva-anagrelide-capsules-recall-failed-dissolution-testing-risk. Based on FDA recall #D-0992-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0992-2022%22&limit=1).
Why it’s dangerous
The capsules failed dissolution testing, meaning they may not release the medication properly. This could lead to the drug not working as intended, but it does not cause immediate harm.
Who’s affected
People with a prescription for Anagrelide Capsules 0.5 mg, 100-count bottles. Those who have the specific lot number GD01090 are most at risk.
How to tell if you have this one
Check for the NDC code 0172-5241-60 and lot number GD01090 on the bottle. The product is a prescription-only 0.5 mg capsule.
- Brand
Teva- Category
Drug
What to do — step by step
Check Your Product
Look for the NDC code 0172-5241-60 and lot number GD01090 on the bottle.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Distributed Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 22 months after the firm started it.
- Firm started the recall
- FDA classified it Class I
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Teva recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0992-2022 (May 11, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0992-2022 to see it in context.
- Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.